Cortexyme (CRTX) Competitors $1.78 -0.17 (-8.72%) As of 10/7/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesTrendsBuy This Stock CRTX vs. OMCL, HSTM, MDRX, PLX, IKT, IZTC, CVM, ZIVO, JATT, and ALVRShould you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include Omnicell (OMCL), HealthStream (HSTM), Veradigm (MDRX), Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), CEL-SCI (CVM), ZIVO Bioscience (ZIVO), JATT Acquisition (JATT), and AlloVir (ALVR). Cortexyme vs. Its Competitors Omnicell HealthStream Veradigm Protalix BioTherapeutics Inhibikase Therapeutics Invizyne Technologies CEL-SCI ZIVO Bioscience JATT Acquisition AlloVir Cortexyme (NASDAQ:CRTX) and Omnicell (NASDAQ:OMCL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment. Do insiders and institutionals have more ownership in CRTX or OMCL? 63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by company insiders. Comparatively, 2.5% of Omnicell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is CRTX or OMCL more profitable? Omnicell has a net margin of 2.01% compared to Cortexyme's net margin of 0.00%. Omnicell's return on equity of 4.27% beat Cortexyme's return on equity.Company Net Margins Return on Equity Return on Assets CortexymeN/A -70.96% -63.53% Omnicell 2.01%4.27%2.44% Do analysts prefer CRTX or OMCL? Omnicell has a consensus price target of $46.71, indicating a potential upside of 48.54%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than Cortexyme.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cortexyme 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Omnicell 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38 Which has stronger earnings & valuation, CRTX or OMCL? Omnicell has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCortexymeN/AN/A-$89.94M-$2.97-0.60Omnicell$1.11B1.30$12.53M$0.5062.90 Does the media refer more to CRTX or OMCL? In the previous week, Omnicell had 5 more articles in the media than Cortexyme. MarketBeat recorded 7 mentions for Omnicell and 2 mentions for Cortexyme. Omnicell's average media sentiment score of 0.67 beat Cortexyme's score of 0.00 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cortexyme 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Omnicell 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, CRTX or OMCL? Cortexyme has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. SummaryOmnicell beats Cortexyme on 13 of the 15 factors compared between the two stocks. Get Cortexyme News Delivered to You Automatically Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRTX vs. The Competition Export to ExcelMetricCortexymeBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.67M$359.31M$6.10B$10.65BDividend YieldN/AN/A5.70%4.74%P/E Ratio-0.60N/A85.5527.59Price / SalesN/A447.00622.26138.47Price / CashN/A22.4437.7861.77Price / Book0.453.9213.136.76Net Income-$89.94M-$133.30M$3.30B$275.88M7 Day Performance9.20%4.28%5.27%3.71%1 Month Performance10.56%21.08%9.93%10.21%1 Year Performance154.29%21.92%87.76%35.85% Cortexyme Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRTXCortexymeN/A$1.78-8.7%N/A+154.2%$53.67MN/A-0.6055High Trading VolumeOMCLOmnicell3.8549 of 5 stars$30.07-0.9%$46.71+55.4%-28.4%$1.38B$1.15B60.163,670Analyst ForecastHSTMHealthStream4.7209 of 5 stars$28.26-2.4%$31.00+9.7%-5.5%$837.48M$295.21M42.171,093Analyst ForecastMDRXVeradigm2.7438 of 5 stars$4.65flat$13.00+179.6%-47.8%$503.43M$1.53B0.008,000News CoveragePLXProtalix BioTherapeutics2.0064 of 5 stars$2.22+2.5%$15.00+577.2%+145.1%$176.61M$61.95M-17.04200IKTInhibikase Therapeutics1.3576 of 5 stars$1.60+4.6%$6.50+306.3%+29.6%$119.23MN/A-0.606IZTCInvizyne TechnologiesN/A$14.50-6.3%N/AN/A$90.65MN/A0.0029CVMCEL-SCIN/A$9.04+2.5%N/AN/A$62.21MN/A-18.8343ZIVOZIVO Bioscience0.1356 of 5 stars$15.99+15.0%N/A-38.7%$61.03M$15.85K-3.2810Gap UpJATTJATT AcquisitionN/A$2.99+24.1%N/A-4.8%$51.58MN/A0.003News CoverageHigh Trading VolumeALVRAlloVirN/A$6.35+13.2%N/A-56.4%$32.02MN/A-0.31110High Trading Volume Related Companies and Tools Related Companies Omnicell Alternatives HealthStream Alternatives Veradigm Alternatives Protalix BioTherapeutics Alternatives Inhibikase Therapeutics Alternatives Invizyne Technologies Alternatives CEL-SCI Alternatives ZIVO Bioscience Alternatives JATT Acquisition Alternatives AlloVir Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRTX) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored3 Major A.I. Threats That Could Upend the U.S. EconomyThe media's calling Artificial Intelligence a "revolution," but for many Americans, the real impact might actu...Goldco Precious Metals | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cortexyme, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cortexyme With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
